Advertisement
For patients with type 2 diabetes mellitus

Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM

0
Intervention effective for reducing cardiovascular risk in patients with type 2 diabetes
For pediatric and adolescent oncology patients

Single-Dose PCV13 Immunogenic, Safe in Pediatric Oncology

0
After vaccination, ≥70 percent had protective antibody titers for S. pneumoniae serotypes
In a report published online July 16 in the Journal of Clinical Pharmacy and Therapeutics

Survival Feasible Post Acute Liver Failure Secondary to Amiodarone

0
Case report describes survival of 79-year-old woman treated with IV amiodarone for atrial flutter
Postoperative pain is frequently underrated when assessed by nursing staff on wards

Post-Op Pain May Often Be Underrated by Inpatient Staff

0
Cross sectional data comparison of pain assessment showed large gap of underrated pain
High doses of vitamin D don't protect children from upper respiratory tract infections in the winter

High-Dose Vitamin D No Help for Winter URIs in Children

0
High dose supplementation did not reduce overall wintertime upper respiratory tract infections
Reductions in opioid dosing might improve pain and function

Reduction of Opioid Dose May Improve Pain, Quality of Life

0
Opioid tapering involved slowly decreasing dose over time, study author says
Animal research may have yielded a potential treatment for fetal alcohol spectrum disorder in children; the new report was published online July 18 in Molecular Psychiatry.

Animal Study Reveals Potential of Fetal Alcohol Damage Reversal

0
Two common medications show promise in lab rats, researchers report
As of 2015

CDC: >100 Million Americans Have Diabetes or Prediabetes

0
Diabetes was seventh leading cause of death in 2015 in United States, according to report
Hospitalists have an important role to play in mitigating opioid use disorder

Hospitalists Have Role to Play in Mitigating Opioid Use Disorder

0
Hospitalists must use opioids judiciously, including adhering to specific dose limits, setting expectations
Nerlynx (neratinib) has been approved by the U.S. Food and Drug Administration to help prevent human epidermal growth factor receptor type 2-positive breast cancer from returning.

FDA Approves Nerlynx to Help Prevent HER2+ Breast CA Return

0
Drug is a kinase inhibitor that works by blocking several enzymes that promote cell growth